Individualized treatment effects of corticosteroids in IgA nephropathy
Preprint
Abstract
IgA nephropathy (IgAN) is a leading cause of kidney failure with diverse clinical presentations and treatment responses, particularly to corticosteroids, with conflicting evidence. Due to potentially severe side effects and heterogenous responses more individualized approaches are needed. We developed a causal machine learning framework for predicting individualized treatment effects of corticosteroids in IgAN by integrating clinical variables, histopathological scores, and deep learning-based biomarkers from digitized kidney biopsies (pathomics) of 1,022 patients from eight retrospective international cohorts. At the cohort-level, corticosteroids showed no significant effect on five-year kidney survival. However, the framework identified subpopulations with and without significant treatment benefit, improving progression-free kidney survival and also reducing overtreatment in low-benefit patients. Pathomics highlighted tubulointerstitial inflammation and glomerular tuft deformation as predictors of corticosteroid response. Our framework offers a blueprint for precision therapy in IgAN, supporting clinical decision-making in the era of emerging targeted treatments.Keywords
This publication has 30 references indexed in Scilit:
- Clinical relevance of computationally derived tubular features and their spatial relationships with the interstitial microenvironment in minimal change disease/focal segmental glomerulosclerosisKidney International, 2025
- An Expert Opinion on Current and Future Treatment Approaches in IgA NephropathyAdvances in Therapy, 2025
- Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trialThe Lancet, 2023
- Next-Generation Morphometry for pathomics-data mining in histopathologyNature Communications, 2023
- After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathyKidney International, 2020
- Severe Adverse Effects Associated With Corticosteroid Treatment in Patients With IgA NephropathyKidney International Reports, 2017
- Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working GroupKidney International, 2017
- Prognostic value of endocapillary hypercellularity in IgA nephropathy patients with no immunosuppressionJournal Of Nephrology, 2015
- Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatmentsKidney International, 2014
- Corticosteroids in IgA nephropathy: a randomised controlled trialThe Lancet, 1999